SAB Biotherapeutics Warrant
SABSW
21 hedge funds and large institutions have $3.86M invested in SAB Biotherapeutics Warrant in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 10 closing their positions.
4% less capital invested
Capital invested by funds: $4.04M → $3.86M (-$178K)
13% less funds holding
Funds holding: 24 → 21 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$840K |
| 2 |
FBCM
Fort Baker Capital Management
Larkspur,
California
|
+$67.3K |
| 3 |
Morgan Stanley
New York
|
+$57.6K |
| 4 |
CCM
Context Capital Management
Lajolla,
California
|
+$43K |
| 5 |
BCM
Bluefin Capital Management
New York
|
+$35.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCAM
Owl Creek Asset Management
New York
|
-$242K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$214K |
| 3 |
KC
Kepos Capital
New York
|
-$183K |
| 4 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$171K |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$161K |
SABSW Hedge Fund Activity: Q4 2021 in Review
21 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q4 2021, worth a combined $3.86M — down 4.4% from $4.04M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SABSW and 7 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Shaolin Capital Management, adding an estimated $840K. The largest seller was Owl Creek Asset Management, exiting entirely with an estimated $242K sold.
- 21 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q4 2021, down from 24 in Q3 2021.
- Funds reported $3.86M of SAB Biotherapeutics Warrant stock for Q4 2021, down 4.4% quarter-over-quarter.
- 7 funds opened new SAB Biotherapeutics Warrant positions in Q4 2021 and 10 closed out, a net change of -3 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q4 2021 was Shaolin Capital Management, an estimated $840K added.
- The largest SAB Biotherapeutics Warrant seller in Q4 2021 was Owl Creek Asset Management, an estimated $242K sold.
Based on aggregated 13F filings for Q4 2021.